CClinicalTrials.gg
CompletedNCT05312866Updated Dec 16, 2022

Intraoperative Retrolaminar Block as Opioid Free Anesthesia After Posterior Lumber Spine Discectomy

An interventional study of Standard analgesia (paracetamol +fentanyl) and Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone in Opioid Free Anesthesia, sponsored by Zagazig University. Completed at 1 site in Egypt. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-16.

Sponsored by Zagazig University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

Opioid-free intraoperative protocols have been successfully used in specific surgical populations with equal or superior results to classic general anesthetic approaches. In instances where opioid-free anesthesia may not be entirely feasible, there exists a continually growing body of evidence that the modern anesthesiologist has a potent pharmacologic and regional anesthetic arsenal that can reduce the amount of opioids required to effectively treat pain.

Retrolaminar block is considered a new, easy and simple technique with decreasing incidence of complications such as hypotension, pleural and nerve injury. Its efficacy had been investigated in trauma patients

Read the detailed description
  • Null hypothesis: Intraoperative retrolaminar block will not produce opioid sparing anesthetic effect and enhanced recovery after posterior lumber spine discectomy.
  • Alternative hypothesis: Intraoperative retrolaminar block will produce opioid sparing anesthetic effect and enhanced recovery after posterior lumber spine discectomy.
02

Conditions studied

  • Opioid Free Anesthesia
03

In context

Lead sponsor

Zagazig University is the lead sponsor of 447 studies on the registry; 75 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Written informed consent from the patient.
  • Age: 21-60 years old.
  • Sex: both sex (males and females).
  • American Society of Anesthesiologist Physical status: ASA 1\& II.
  • Body Mass Index (BMI) = (25-30 kg/m2).
  • Type of operation: elective posterior Lumbar discectomy from L3 to L5 disc space.

Exclusion criteria

Exclusion Criteria:

  • Altered mental state.
  • Patients with known history of allergy to study drugs.
  • Advanced hepatic, renal, cardiovascular, and respiratory diseases.
  • Patients with chronic pain.
  • Patients receiving anticoagulants.
  • Contraindications of regional anesthesia, e.g., allergy to local anesthetics, coagulopathy, or septic focus at site of injection.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Active comparator
    Standard analgesia (paracetamol +fentanyl)

    Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv

    Procedure: Standard analgesia (paracetamol +fentanyl)

  • Active comparator
    Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone

    Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.

    Procedure: Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone

Interventions

  • ProcedureStandard analgesia (paracetamol +fentanyl)

    Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv

  • ProcedureRetrolaminar block with bupivacaine + magnesium sulfate + dexamethasone

    Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.

06

What researchers measure

Primary outcomes

  1. The recovery time

    The recovery time (time from discontinuation of isoflurane to first response to verbal command) will be recorded, then the patient will be transferred to the post anesthesia care unite (PACU) on standard monitors.

    Time frame: up to 1 hour postoperative

Secondary outcomes

  1. pain intensity

    pain intensity measured using visual analogue scale from 0= no pain to 10= worst pain

    Time frame: up to 24 hours postoperative

07

Study locations

1 site
  • Faculty of Human Medicine, Zagazig University
    Zagazig, Alsharquia 44511, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05312866
Lead sponsor
Zagazig University
Responsible party
Alshaimaa Abdel Fattah Kamel (principle investigator, Zagazig University) — Principal investigator
First posted
Apr 6, 2022
Start date
May 1, 2022
Primary completion
Dec 1, 2022
Completion
Dec 1, 2022
Last update
Dec 16, 2022

Study contacts

Alshaimaa Kamel, M.D
principal investigator · Zagazig University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion